InsmedINSM
$121.2+2.6%11월 13일 종가 기준
시가총액 $26.6B
3달 전보다 +4.0%
최고 $134.75최저 $93.33
세로선 = 임상·딜 이벤트 · 차트 위에서 스크롤하면 확대·축소, 확대 중엔 가로로 넘겨볼 수 있어요
지켜보기 의견AI 점수 65 / 100
진행 중인 임상과 AI 예측
- Phase 3TPIP 흡입분말 진행성 폐섬유증 치료 효능·안전성 임상시작 전A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)29%
- Phase 1폐동맥고혈압 흡입제 TPIP 간기능별 약동학 임상시작 전A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment46%
- Phase ?폐동맥고혈압 환자 대상 흡입형 분말 TPIP 임상AVAILABLEAn Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)20%
- Phase 2간질성 폐질환 동반 폐고혈압 치료제 TPIP 흡입분말 연장 임상진행 중An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)2%
- Phase 1뒤센 근이영양증 치료제 INS1201 투여 임상모집 중A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)37%
- Phase 1INS1202 루게릭병 척수강 투여 임상모집 중A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)58%
- Phase 3TPIP 간질성 폐질환 동반 폐고혈압 흡입 치료제 임상모집 중Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)32%
- Phase 2TPIP 분말 흡입형 폐동맥고혈압 치료 연장 임상진행 중An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)0%
- Phase 3폐동맥고혈압 1일 1회 흡입 분말 치료제 TPIP 임상시작 전A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)66%
- Phase 3폐질환 동반 폐고혈압 흡입 치료제 TPIP 임상시작 전An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)32%
- Phase 2중등도-중증 화농성 한선염 대상 브렌소카팁 유효성 및 안전성 임상진행 중A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)51%
성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요. 예측이 없는 임상 1건은 생략했어요.